Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Irinotecan in Solid Tumors
NCT03295084Phase 1Completed
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan in solid tumor and metastatic colorectal cancer (mCRC) (2 arms). Primary endpoints: Maximal Tolerated Dose and Dose Limiting Toxicity. Started Jul 2015; status: completed.
02
Drugs
irinotecan
03
Conditions
solid tumormetastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03295084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295084.